Schizophrenia drug Risperdal is arranged in a Cambridge, Massachusetts pharmacy Tuesday, October 17th. Johnson & Johnson said third-quarter earnings rose 8.7 percent led by sales of prescription drugs inlcuding the schizophrenia drug Risperdal. Schizophrenia drug Risperdal. Photo: Bloomberg

The $8 billion Risperdal verdict last week against Johnson & Johnson raised an increasingly common question: What convinces jurors to come back with such stratospheric awards?

Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader

Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Amanda Bronstad

Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Law.com Class Actions: Critical Mass. She is based in Los Angeles.

Coverage & Policy Issues
Regulation/Legislation
Litigation
Corporate Risk